Related Experiment Videos
Investigational new drug applications; clinical holds--FDA. Direct final rule
Abstract:
The Food and Drug Administration (FDA) is amending its regulations governing investigational new drug applications (IND's) for human drug and biological products. This action amends the IND clinical hold requirements to state that the agency will respond in writing to a sponsor's request that a clinical hold be removed from an investigation within 30-calendar days of the agency's receipt of the request and the sponsor's complete response to the issue(s) that led to the clinical hold. FDA is taking this action in accordance with provisions of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act). Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed rule under FDA's usual procedure for notice-and-comment rulemaking to provide a procedural framework to finalize the rule in the event the agency receives significant adverse comments and withdraws this direct final rule.
Insights
The Food and Drug Administration (FDA) now requires a 30-day written response to requests for removing clinical holds on investigational new drug applications (INDs). This change streamlines the drug development process for human drugs and biological products.
Area of Science:
- Regulatory Affairs
- Pharmaceutical Science
Background:
- The Food and Drug Administration (FDA) regulates investigational new drug applications (INDs).
- Clinical holds can delay drug development and product approval.
- Expedited review processes are crucial for timely access to novel therapies.
Purpose of the Study:
- To amend regulations for IND clinical hold removal requests.
- To establish a defined timeline for FDA response to sponsors.
- To comply with the Food and Drug Administration Modernization Act of 1997.
Main Methods:
- Amending existing FDA regulations.
- Implementing a 30-calendar-day response window for clinical hold removal requests.
- Publishing a companion proposed rule for notice-and-comment rulemaking.
Main Results:
- Sponsors will receive a written response from the FDA within 30 calendar days.
- The response is contingent upon receipt of the request and a complete sponsor response to identified issues.
- This direct final rule aims to expedite the resolution of clinical holds.
Conclusions:
- The updated IND clinical hold requirements aim to improve regulatory efficiency.
- A predictable response timeline facilitates smoother drug development pathways.
- This regulatory amendment supports the timely advancement of human drug and biological products.